This instrument is the Financial Framework (Supplementary Powers) Amendment (Health Measures No. 5) Regulations 2020.

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is registered.	17 October 2020

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under the Financial Framework (Supplementary Powers) Act 1997.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

Financial Framework (Supplementary Powers) Regulations 1997

1 In the appropriate position in Part 4 of Schedule 1AB (table)

Insert:

444

Support for Australia’s Thalidomide Survivors

To provide support to thalidomide survivors, including by providing funding for:

(a) the establishment of a national site of recognition for thalidomide survivors and their families, in the form of a public memorial; and

(b) payments to thalidomide survivors to:

(i) acknowledge the pain and suffering experienced throughout their lives; and

(ii) meet their increased health needs due to early onset ageing; and

(c) an Extraordinary Assistance Fund through which thalidomide survivors will be given funds to assist them to adapt their homes, vehicles and environment; and

(d) a national disability support service to assist thalidomide survivors to identify and gain access to specific thalidomide‑related supports and services; and

(e) a Health Care Assistance Fund through which thalidomide survivors will be given funds to assist them with out‑of‑pocket health care expenses.

This objective has the effect it would have if it were limited to measures:

(a) with respect to postal, telegraphic, telephonic, and other like services (within the meaning of paragraph 51(v) of the Constitution); or

(b) providing, or incidental to the provision of, pharmaceutical benefits, sickness benefits and medical services (within the meaning of paragraph 51(xxiiiA) of the Constitution); or

(i) the Convention on the Rights of Persons with Disabilities, particularly Articles 4 and 25;

(ii) the International Covenant on Economic, Social and Cultural Rights, particularly Articles 2 and 12; or

(d) undertaken in, or in relation to, a Territory.